Dr. Luyao Wang earned her Ph.D. in Biomedicne from Hong Kong Baptist University (HKBU) in 2021. In 2024, she was appointed as Research Assistant Professor at the School of Chinese Medicine, HKBU. Since 2023, she has served as Laboratory Director at the Lau Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ), HKBU.

Dr. Wang’s research focuses on bone and cardiovascular diseases, with expertise in molecular target discovery within specific protein domains and aptamer-based translational medicine and drug discovery. Over the past decade, she has published over 10 SCI-indexed papers as (co-)first author and/or (co-)corresponding author in journals including Nature Communications, Advanced Science, Biomaterials, and Theranostics.

Her pioneering work demonstrated that sclerostin protein exerts bone formation-inhibiting effects and cardiovascular-protective functions through distinct structural domains. She identified the cardiovascular-safe bone anabolic target - sclerostin loop3, developed Apc001, a therapeutic aptamer specifically targeting sclerostin loop3 (Chinese Patent: ZL 2019 8 0012952.6; International Patent: WO 2019/154410). This aptamer obtained both Orphan Drug Designation (ODD) and Pediatric Rare Disease Designation (PRDD) from the US-FDA for treating osteogenesis imperfecta and X-linked hypophosphatemic rickets, respectively. It has initiated China’s first industrialization process for a novel aptamer drug (pilot-scale production of active pharmaceutical ingredient completed).

Related clinical and foundational research has been recognized as a representative health/medical achievement for the 25th Anniversary of the Establishment of Hong Kong SAR, and awarded the First Prize of Shanghai Science and Technology Progress Award (2023) and the First Prize of Shanghai Medical Science and Technology Award (2023).

Additionally, Dr. Wang served as the Hong Kong representative scientist for the "Tianzhou-1" spacecraft space life science project. She is a registered expert at the ISO International Standards Committee. As PI/Co-PI, she currently leads two General Research Fund (GRF) projects (12102223, 12102524) from the Hong Kong Research Grants Council (RGC) and one National Natural Science Foundation of China (NSFC) Young Scientists Fund (Category C) (82300988). She has also contributed to the completion of one National Key R&D Program of China (2018YFA0800800), one RGC Theme-based Research Scheme (T12-201/20-R), and one Guangdong Basic and Applied Basic Research Key Fund (2019B1515120089), etc..

簡歷

王璐瑤博士于2021年畢業於香港浸會大學，獲得生物醫學博士學位。2024年受聘香港浸會大學中醫藥學院助理教授（研究）。2023年始，擔任香港浸會大學羅守輝骨與關節疾病轉化醫學研究所實驗室主任。

王璐瑤博士長期從事骨與心血管系統疾病相關研究工作，特色研究方向包括蛋白特定結構域的分子靶點發現與機制研究，以及基於核酸適配子的轉化研究及藥物發現。近十年，作為（共同）第一作者及（共同）通讯作者，發表包括Nature Communications, Advanced Science, Biomaterials及Theranostics在內的SCI論文十餘篇。首次研究發現硬骨抑素蛋白可通過不同結構域發揮對骨形成的抑制作用和對心血管系統的保護作用，鑒定了心血管安全的促成骨靶點-硬骨抑素loop3，開發了特異性靶向硬骨抑素loop3的治療性核酸適配子Apc001（中國專利：ZL 2019 8 0012952.6，國際專利：WO 2019/154410），治療成骨不全症及治療低磷佝僂病先後獲得了US-FDA孤兒藥認定及兒科罕見病認定，並開啟了中國首個核酸適配子新藥的產業化進程（已完成原料藥中試生產）；項目相關臨床及基礎研究工作獲香港特別行政區回歸25週年健康醫學代表性研究成果、上海市科技進步一等獎（2023）、上海醫學科技一等獎（2023）等。此外，申报人为“天舟一号”空间生命科学项目香港代表科学家，ISO国际标准委员会注册专家等；主持了 2 項香港特别行政区研究资助局優配研究项目（12102223，12102524）、1 項國家自然青年科學基金（C類）（NSFC 82300988）；參與完成了 1 项国家重点研发计划（2018YFA0800800）、 1 项香港特别行政区研究资助局主题研究计划（T12-201/20-R）、1 项广东省基础与应用基础研究重點基金项目（2019B1515120089）等。